|
1
|
Hua F, Li CH, Chen XG and Liu XP: Daidzein
exerts anticancer activity towards SKOV3 human ovarian cancer cells
by inducing apoptosis and cell cycle arrest and inhibiting the
Raf/MEK/ERK cascade. Int J Mol Med. 41:3485–3492. 2018.PubMed/NCBI
|
|
2
|
Bareiss PM, Paczulla A, Wang H, Schairer
R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler
A, et al: SOX2 expression associates with stem cell state in human
ovarian carcinoma. Cancer Res. 73:5544–5555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolterink S, Moldenhauer G, Fogel M,
Kiefel H, Pfeifer M, Lüttgau S, Gouveia R, Costa J, Endell J,
Moebius U and Altevogt P: Therapeutic antibodies to human L1CAM:
Functional characterization and application in a mouse model for
ovarian carcinoma. Cancer Res. 70:2504–2515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang S, Xie B, Wang L, Yang H, Zhang H,
Chen Y, Wang F, Liu C and He H: Macrophage-mediated vascular
permeability via VLA4/VCAM1 pathway dictates ascites development in
ovarian cancer. J Clin Invest. 131:e1403152021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campbell S and Gentry-Maharaj A: The role
of transvaginal ultrasound in screening for ovarian cancer.
Climacteric. 21:221–226. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Varughese J, Cocco E, Bellone S, Bellone
M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S
and Santin AD: High-grade, chemotherapy-resistant primary ovarian
carcinoma cell lines overexpress human trophoblast cell-surface
marker (Trop-2) and are highly sensitive to immunotherapy with
hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol.
122:171–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alhazzazi TY, Kamarajan P, Joo N, Huang
JY, Verdin E, D'Silva NJ and Kapila YL: Sirtuin-3 (SIRT3), a novel
potential therapeutic target for oral cancer. Cancer.
117:1670–1678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taylor DM, Maxwell MM, Luthi-Carter R and
Kazantsev AG: Biological and potential therapeutic roles of sirtuin
deacetylases. Cell Mol Life Sci. 65:4000–4018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alhazzazi TY, Kamarajan P, Verdin E and
Kapila YL: SIRT3 and cancer: Tumor promoter or suppressor? Biochim
Biophys Acta. 1816:80–88. 2011.PubMed/NCBI
|
|
10
|
Desouki MM, Doubinskaia I, Gius D and
Abdulkadir SA: Decreased mitochondrial SIRT3 expression is a
potential molecular biomarker associated with poor outcome in
breast cancer. Hum Pathol. 45:1071–1077. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HS, Patel K, Muldoon-Jacobs K, Bisht
KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage
J, Owens KM, et al: SIRT3 is a mitochondria-localized tumor
suppressor required for maintenance of mitochondrial integrity and
metabolism during stress. Cancer Cell. 17:41–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang B, Fu X, Shao L, Ding Y and Zeng D:
Aberrant expression of SIRT3 is conversely correlated with the
progression and prognosis of human gastric cancer. Biochem Biophys
Res Commun. 443:156–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quan Y, Wang N, Chen Q, Xu J, Cheng W, Di
M, Xia W and Gao WQ: SIRT3 inhibits prostate cancer by
destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt
pathway. Oncotarget. 6:26494–26507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carson AR, McTiernan CF, Lavery L, Hodnick
A, Grata M, Leng X, Wang J, Chen X, Modzelewski RA and Villanueva
FS: Gene therapy of carcinoma using ultrasound-targeted microbubble
destruction. Ultrasound Med Biol. 37:393–402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen S and Grayburn PA:
Ultrasound-targeted microbubble destruction for cardiac gene
delivery. Methods Mol Biol. 1521:205–218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Villanueva FS: Ultrasound mediated
destruction of DNA-loaded microbubbles for enhancement of
cell-based therapies: New promise amidst a confluence of
uncertainties? JACC Cardiovasc Imaging. 2:880–882. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao F, Wu J, Niu S, Sun T, Li F, Bai Y,
Jin L, Lin L, Shi Q, Zhu LM and Du L: Biodegradable, pH-sensitive
hollow mesoporous organosilica nanoparticle (HMON) with controlled
release of pirfenidone and
ultrasound-target-microbubble-destruction (UTMD) for pancreatic
cancer treatment. Theranostics. 9:6002–6018. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jing H, Cheng W, Li S, Wu B, Leng X, Xu S
and Tian J: Novel cell-penetrating peptide-loaded nanobubbles
synergized with ultrasound irradiation enhance EGFR siRNA delivery
for triple negative breast cancer therapy. Colloids Surf B
Biointerfaces. 146:387–395. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhong S, Shu S, Wang Z, Luo J, Zhong W,
Ran H, Zheng Y, Yin Y and Ling Z: Enhanced homing of mesenchymal
stem cells to the ischemic myocardium by ultrasound-targeted
microbubble destruction. Ultrasonics. 52:281–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
22
|
Zatroch KK, Knight CG, Reimer JN and Pang
DS: Refinement of intraperitoneal injection of sodium pentobarbital
for euthanasia in laboratory rats (Rattus norvegicus). BMC Vet Res.
13:602017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kopaladze RA: Methods for the euthanasia
of experimental animals-the ethics, esthetics and personnel safety.
Usp Fiziol Nauk. 31:79–90. 2000.(In Russian). PubMed/NCBI
|
|
24
|
Yao W, Ji S, Qin Y, Yang J, Xu J, Zhang B,
Xu W, Liu J, Shi S, Liu L, et al: Profilin-1 suppresses
tumorigenicity in pancreatic cancer through regulation of the
SIRT3-HIF1α axis. Mol Cancer. 13:1872014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paolillo M and Schinelli S: Extracellular
matrix alterations in metastatic processes. Int J Mol Sci.
20:49472019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown GT and Murray GI: Current
mechanistic insights into the roles of matrix metalloproteinases in
tumour invasion and metastasis. J Pathol. 237:273–281. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu Y, Liu J and Huang H: Recent agents
targeting HIF-1α for cancer therapy. J Cell Biochem. 114:498–509.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen ZY, Liang K, Sheng XJ, Si-Tu B, Sun
XF, Liu JQ, Qiu RX, Zhang H, Li YW, Zhou XX and Yu JX: Optimization
and apoptosis induction by RNAi with UTMD technology in
vitro. Oncol Lett. 3:1030–1036. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su J, Wang J, Luo J and Li H:
Ultrasound-mediated destruction of vascular endothelial growth
factor (VEGF) targeted and paclitaxel loaded microbubbles for
inhibition of human breast cancer cell MCF-7 proliferation. Mol
Cell Probes. 46:1014152019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stromar IK and Jakic-Razumovic J: The
value of immunohistochemical determination of topoisomerase IIα and
Ki67 as markers of cell proliferation and malignant transformation
in colonic mucosa. Appl Immunohistochem Mol Morphol. 22:524–529.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao J, Dong D and Sun L, Zhang G and Sun
L: Prognostic significance of the epithelial-to-mesenchymal
transition markers e-cadherin, vimentin and twist in bladder
cancer. Int Braz J Urol. 40:179–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiang XY, Kang JS, Yang XC, Su J, Wu Y,
Yan XY, Xue YN, Xu Y, Liu YH, Yu CY, et al: SIRT3 participates in
glucose metabolism interruption and apoptosis induced by BH3
mimetic S1 in ovarian cancer cells. Int J Oncol. 49:773–784. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Yao Y, Ding H and Chen R:
Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins
and activating caspase-3/caspase-9 pathway in human leukemia HL-60
cells. Tumour Biol. 35:5409–5415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu J, Wang Y, Li Z, Wang Q, Zhou X and Wu
W: Ultrasound-targeted microbubble destruction (UTMD) combined with
liposome increases the effectiveness of suppressing proliferation,
migration, invasion, and epithelial-mesenchymal transition (EMT)
via targeting metadherin (MTDH) by ShRNA. Med Sci Monit.
25:2640–2648. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liao Y, Luo H, He Z, Kuang Y, Chen P,
Zhang X, Chen J, Wen Q, Xie Y and Ding S: A combination of
UTMD-mediated HIF-1 α shRNA transfection and TAE in the treatment
of hepatic cancer. Biomed Res Int. 2019:19374602019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Y, Fu LL, Wen X, Wang XY, Liu J,
Cheng Y and Huang J: Sirtuin-3 (SIRT3), a therapeutic target with
oncogenic and tumor-suppressive function in cancer. Cell Death Dis.
5:e10472014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang L, Wang WY and Cao LP: SIRT3 inhibits
cell proliferation in human gastric cancer through down-regulation
of notch-1. Int J Clin Exp Med. 8:5263–5271. 2015.PubMed/NCBI
|
|
39
|
Xu LX, Hao LJ, Ma JQ, Liu JK and Hasim A:
SIRT3 promotes the invasion and metastasis of cervical cancer cells
by regulating fatty acid synthase. Mol Cell Biochem. 464:11–20.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Ren X, Cheng Y, Huber-Keener K,
Liu X, Zhang Y, Yuan YS, Yang JW, Liu CG and Yang JM:
Identification of sirtuin 3, a mitochondrial protein deacetylase,
as a new contributor to tamoxifen resistance in breast cancer
cells. Biochem Pharmacol. 86:726–733. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dong XC, Jing LM, Wang WX and Gao YX:
Down-regulation of SIRT3 promotes ovarian carcinoma metastasis.
Biochem Biophys Res Commun. 475:245–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu Y, Gao WN, Xue YN, Zhang LC, Zhang JJ,
Lu SY, Yan XY, Yu HM, Su J and Sun LK: SIRT3 aggravates
metformin-induced energy stress and apoptosis in ovarian cancer
cells. Exp Cell Res. 367:137–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Boreddy SR, Sahu RP and Srivastava SK:
Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and
invasion by inhibiting HIF-α/VEGF/Rho-GTPases: Pivotal role of
STAT-3. PLoS One. 6:e257992011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fujita M, Yasuda M, Kitatani K, Miyazawa
M, Hirabayashi K, Takekoshi S, Iida T, Hirasawa T, Murakami M,
Mikami M, et al: An up-to-date anti-cancer treatment strategy
focusing on HIF-1alpha suppression: Its application for refractory
ovarian cancer. Acta Histochem Cytochem. 40:139–142. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bell EL, Emerling BM, Ricoult SJ and
Guarente L: SirT3 suppresses hypoxia inducible factor 1α and tumor
growth by inhibiting mitochondrial ROS production. Oncogene.
30:2986–2996. 2011. View Article : Google Scholar : PubMed/NCBI
|
